Nevertheless, introduction of the additional steps in the coating preparation (i.e., mercaptosilanization and reduction) provides higher degree of antibody immobilization on the surface. of hemolytic response. Thus, proposed biofunctionalized CD133 antibody AVC surface POLDS has shown sufficient stability for adapting as cardiovascular implant coating and biocompatibility. According to conducted in vitro studies, the modified surface can be further tested for applications in various biological systems. Keywords: bioresorbable polymer-based coating, vascular implants, antibody immobilization, stent surface biocompatibility 1. Introduction Nowadays, numerous RET-IN-1 studies are carried out on coatings that are biofunctionalized with various biocompounds and biomolecules in order to obtain the coating specific properties. The functionalized material surfaces with antibodies are of particular interest. Immobilized anti-epithelial cell adhesion antibodies have found application in circulating tumor cells capture to prevent metastases development [1] in endothelial progenitor cells capture, which differentiate into a mature endothelium, thus increasing cardiovascular stents biocompatibility [2,3,4,5,6,7] in RET-IN-1 biosensor design and construction as well as diagnostic platforms with significantly improved detection efficiency [8,9]. Nevertheless, the critically important factor to be considered RET-IN-1 still remains, like immobilization efficiency of a well-oriented antibody onto the surface to achieve high molecule loading with affinity retention [9,10]. The different surface antibody immobilization methods have been extensively studied. Among various strategies, the physical adsorption [11,12], covalent bonding [11,12,13,14] or bio-affinity immobilization approach [15] can be distinguished. The application of the endothelial cell (EC) and its progenitor cell specific (endothelial progenitor cell C EPC) antibodies have, therefore, found a special place in the surface modification of cardiovascular stents. Bare metal stents (BMS) were first introduced in the mid 1990s, quickly becoming a very powerful tool in modern interventional cardiology. This approach allowed to overcome some of the major difficulties of the early balloon angioplasty procedure, such as an elastic recoil and RET-IN-1 blood vessel reocclusion in the early stage of the intervention. However, some of the long-term problems, like restenosis and thrombosis still remained unsolved [16]. To overcome some of these problems, subsequently, drug eluting stents (DES) were developed. First generation of DES was introduced in the early 2000s and consisted of three main components: Metal scaffold, polymer coating and drug incorporated into the polymer structure [17,18]. The next step in the intravascular implants improvement were the bioresorbable scaffolds (BRS). Their primary objectives were to provide a temporary vessel support, prevent acute and late recoil, avoid stent fracture and also to address the issue of chronic inflammation and RET-IN-1 late stent thrombosis [19,20,21]. Apart from stent structure and material modifications, there are also specific implant surface biofunctionalizations proposed, including various biomolecules and bionanocomposites. Some of these methods use polymeric nanoparticles architecture wherein drug molecules are encapsulated and delivered to a target of interest [22]. Another approach to stents biofunctionalization is usually to cover its surface with bionanocomposite with immobilized biomolecules designed to capture endothelial progenitor cells [2,23]. Once captured EPCs differentiate into a mature endothelium, thus increasing stents biocompatibility [4,5,7,24]. One of the approaches was to use immobilization of anti-CD34 antibodies, for biofunctionalization of stent, but such surface tends to have insufficient biocompatibility. Therefore, attracting EPCs emerged as alternative strategy. Use of EPCs specific anti-CD133 coated surface has been shown to have high reendothelialization rate, when used in stents [23,24]. In this work, we present novel coating facilitating anti-CD133 antibodies immobilization. Biomolecules were immobilized on a surface covered by the thin film prepared with ammonium acryloyldimethyltaurate/vinylpyrrolidone co-polymer (AVC). AVC.
Nevertheless, introduction of the additional steps in the coating preparation (i